Investigational Nasal Spray Modestly Reduces OSA Severity
Researchers have discovered that a bedtime nasal spray has the potential to reduce the severity of OSA and next-day blood pressure.
Researchers have discovered that a bedtime nasal spray has the potential to reduce the severity of OSA and next-day blood pressure.
Medline Industries announced the acquisition of the manufacturing rights and intellectual property of AG Cuffill from Hospitech Respiration Ltd.
The American Lung Association’s 2023 "State of Lung Cancer" report reveals improvement in five-year survival rate across the US, including for people of color.
The guideline provides 12 evidence-based key action statements to guide clinicians in treating patients experiencing symptoms from inhalant allergies.
Lactating mothers who get the COVID-19 booster pass along the antibodies to their children via their breast milk and potentially protect babies too young to receive the vaccine.
Adult ICUs across the nation continue to be challenged by alarm fatigue despite years of work to alleviate this problem.
Aria CV Inc reports its first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System.
The mandibular repositioning device acts by increasing the patient’s airway during sleep, improving the ability to exchange air, thereby reducing the tendency to snore and alleviating signs of OSA.